Socialiya - Entertainment. Knowledge. Community.
FDA delays ruling on AstraZeneca drug after negative adcomm vote

The FDA deferred its ruling on AstraZeneca's camizestrant to review analyses filed after an advisory...

BUSINESS NEWS May 27, 2026

FDA delays ruling on AstraZeneca drug after negative adcomm vote

The FDA deferred its ruling on AstraZeneca's camizestrant to review analyses filed after an advisory committee voted against the breast cancer asset.

3 views 0 likes 0 comments
Share:
The FDA deferred its ruling on AstraZeneca's camizestrant to review analyses filed after an advisory committee voted against the breast cancer asset.

Author: Fierce Biotech

Read Original Article

Related News

Advertisement
socialiya
Advertisement
APNA POS
Advertisement

Top Categories

Advertisement
APNA POS
Advertisement
APNA POS
Advertisement
socialiya
Advertisement
APNA POS